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Objective. The objective of this study was to assess loss of heterozygosity (LOH) in tumor suppressor gene loci in oral
granular cell tumors (GCTs).
Study Design. We assessed LOH in 8 samples of oral GCT using polymorphic microsatellite markers at chromosome regions
3p, 9p, 11q, and 17p, flanking areas close to tumor suppressor genes. We further performed immunohistochemistry to detect
the p53 and Ki-67 proteins and associated these expressions with the molecular results.
Results. Five samples showed LOH in 3 markers at chromosomes 9p and 17p (markers P53, AFM238WF2 and D9S162) with
fraction of allelic loss of 42.8% for each of these markers. No LOH was identified in any other chromosome. LOH was not
associated with the immunohistochemical expression of p53 and Ki-67.
Conclusions. The present study shows LOH at chromosomes 9p and 17p in oral GCTs. (Oral Surg Oral Med Oral Pathol Oral
Radiol 2013;115:249-253)Granular cell tumors (GCTs) are rare benign tumors of
soft tissues, believed to be neural in origin, most likely
derived from Schwann cells.1-4 The etiologic factors
associated with these lesions are unknown.2,3 Few
cases of malignant granular cell tumors have been
reported,5-7 comprising fewer than 2% of GCTs and are
very rare in the head and neck region.8 Molecular
studies related to the etiopathogenesis of GCTs are
scarce.9
Loss of cell cycle control seems important in the de-
velopment of tumors. Deletions in the chromosomal re-
gions of tumor suppressor genes are important because
tumors can develop through alterations in cell cycle con-
trol.10-15 Deletions can be identified using loss of heterozy-
gosity (LOH) analysis: the change from the normal heterozy-
gous state to a homozygous state in paired tumor DNA. It is
considered to be a mechanism of tumor suppressor gene
inactivation during tumorigenesis and is commonly used to
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in a given tumor type. Detecting LOH helps elucidate the
molecular mechanisms underlying tumor development and
provides important information that is useful for disease
diagnosis and prognosis.16 LOH can be identified using dif-
ferent methods, including single nucleotide polymorphism
(SNPs) and microsatellite markers, by comparing the tumor
with constitutive normal tissue. Microsatellite marker analy-
sis is polymerase chain reaction (PCR) based and relies on
identifying the loss of polymorphic markers that flank tumor
suppressor genes.
As LOH is usually investigated in malignant tumors,
sometimes the significance of this finding is overesti-
mated in the literature because it is erroneously re-
garded as a malignant feature; however, it is found in
benign lesions, including oral lesions.12,14,17-19 Al-
though the study of LOH in benign lesions contributes
to the molecular characterization of these lesions, it has
never been explored in GCTs.
In the current study, we evaluated LOH in 8 samples of
oral GCTs using polymorphic microsatellite markers at
chromosome regions 3p, 9p, 11q, and 17p. These chro-
mosomal regions contain important tumor suppressor
genes that are altered in several human neoplasias, includ-
ing tumors of the oral cavity.12,14,15,20-23 Furthermore, as
Statement of Clinical Relevance
As LOH is usually investigated in malignant tu-
mors, sometimes the significance of this finding is
overestimated in the literature because it is errone-
ously regarded as a malignant feature. However,
similar alterations are also observed in some GCTs,
despite its evident benign nature.249
istry.
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also investigated the impact of molecular alterations on
the immunohistochemical expression of the p53 protein.
Additionally, we performed ki-67 immunohistochemistry
(IHC) to test the association between the molecular alter-
ations and cellular proliferation.
MATERIAL AND METHODS
Human tissue
Eight paraffin-embedded tissue samples from 8 differ-
ent patients were obtained from the files of the Oral
Pathology Services of the Universidade Federal de Mi-
nas Gerais (Brazil). Clinical data of the lesions are
displayed in Table I. All samples in this study had the
classic histologic features described for GCTs.3,8 The
local ethics committee approved this study.
DNA isolation
Tumor and normal tissues were microdissected from a
series of 20-m-thick paraffin-embedded tissue sec-
tions under direct visualization using a stereoscopic
microscope. Microdissected tissue was digested with
proteinase K, and genomic DNA was isolated using
Qiagen DNeasy Tissue Kit, following the manufactur-
er’s instructions (Qiagen Inc., Valencia, CA).
LOH analysis
LOH was investigated using a panel of 8 polymorphic
microsatellite markers for multiple genetic loci flanking
regions of tumor suppressor genes. Figure 1 shows the
localization of the markers in relation to the selected
chromosomes. The primers and PCR conditions that
were used are described elsewhere.17 All PCRs were
performed on tumor and normal tissues under the same
conditions. Amplified products were detected using an
ABI PRISM 310 (Applied Biosystems, Foster City,
CA) and analyzed using GeneMapper software version
3.0 (Applied Biosystems).
LOH was calculated as the ratio between the short
allele normal (Sn) and long allele normal (Ln) divided
Table I. Clinical data of the oral granular cell tumor s
Cases Age Gender Lesion site
IHC
ki-67 (%)
IHC
p53 D3S1029 D3
1 34 Female Labial mucosa 0.0  Œ
2 27 Male Tongue 1.4  Œ
3 27 Male Tongue 2.0  Œ
4 45 Female Tongue 0.0  Œ
5 30 Female Palate 1.1  Œ
6 10 Female Labial mucosa 4.1  Œ
7 57 Male Tongue 12.9  Œ
8 17 Female Tongue 2.7 – Œ
Œ, heterozygous; □, homozygous; , positive for the p53 immunoe
FAL, frequency of allelic loss of each case; IHC, immunohistochemby the ratio of the short allele tumor (St) and long alleletumor (Lt), as follows: (Sn:Ln)´(St:Lt). LOH was in-
dicated if one allele decreased by more than 50% in the
tumor sample when compared with the same allele in
normal tissue DNA, after stutter correction when nec-
essary (score 0.5 or 2.0).24 When the DNA from
normal tissue was found to be homozygous for the
polymorphic markers (i.e., showing only one peak cor-
responding to 2 equal-sized alleles), the case was con-
sidered noninformative.
The fractional allelic loss (FAL) was calculated for
each sample and marker by dividing the number of loci
that showed allelic loss by the number of informative
loci.
IHC and statistical analysis
Immunohistochemical reactions to detect ki-67 and p53
proteins were performed following standard procedures
as published elsewhere.25 For each reaction set, a squa-
mous cell carcinoma sample with known reactivity was
used as a positive control, and negative controls were
comprised of cases in which the primary antibody was
omitted. The percentage of the p53 and ki-67–positive
nuclei was obtained by counting nuclear staining in 8
high-power fields (400 magnification). For p53, more
than 10% positive nuclei was considered positive. The
Mann-Whitney test was used to compare the percentage
of the ki-67–positive cells in the lesions with and with-
out LOH at each marker and also to compare the group
of lesions with LOH in at least one marker compared
with the group without LOH at any marker.
RESULTS
The results of LOH and IHC are shown in Table I.
Representative examples of LOH are shown in Figure
2. The average number of informative loci per case was
6.5 (range 5-8). Five tumor samples showed LOH in at
least one marker (Table I). LOH was observed only at
markers p53 (17p13.1), AFM238WF2 (17p13.1), and
D9S162 (9p22-p13). The FAL for each of these 3 loci was
s, immunohistochemistry and LOH results
Microsatellite markers
D9S171 D9S162 D9S157 D11S1369 AFM238WF2 p53 FAL
□ ● Œ Œ □ ● 40.0%
Œ Œ Œ Œ Œ Œ 0.0%
□ Œ Œ □ ● ● 33.3%
□ ● Œ Œ ● □ 33.3%
□ □ Œ □ ● ● 40.0%
□ ● Œ Œ Œ Œ 14.2%
Œ Œ Œ Œ Œ Œ 0.0%
Œ Œ Œ Œ Œ Œ 0.0%
n; –, negative for p53 immunoexpression; ●, loss of heterozygosity;ample
S1293
□
Œ
Œ
Œ
Œ
Œ
Œ
Œ
xpressio42.8%. None of the tumors presented LOH at the mark-
, 9, 11
); Shor
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Volume 115, Number 2 Gomes et al. 251ers D9S171 (9p22–p21), D9S157 (9p22), D11S1369
(11q13.4), D3S1029 (3p21.2), or D3S1293 (3p24.3). Ad-
ditionally, LOH did not show association with ki-67 or
p53. In Figure 3, we show an example with p53 immu-
nopositivity and no LOH with the markers located at
17p13.1.
DISCUSSION
GCT is a rare soft tissue tumor that frequently affects
the head and neck region, mainly the tongue.3,26 A
possible neural origin has been suggested for this tu-
mor, as immunohistochemical studies test positively for
the S-100 antigen.3,8,27,28 Furthermore, this lesion has a
low proliferative potential.28-30 Our immunohistochem-
ical results of ki-67 confirm the low proliferative po-
tential exhibited by GCTs.
Because GCTs are benign, low-prevalence lesions,
their molecular pathogenesis has not been thoroughly
Fig. 1. Microsatellite marker localization in chromosomes 3
Fig. 2. Representative examples of LOH. DNA of tumor sam
tissue. Markers D9S162 (A), p53 (B), and AFM238WF2 (Cinvestigated. Based on a comparative genomic hybrid-ization study with 7 GCT samples (from cerebral, pi-
tuitary, and nervous tissues), the authors of a previous
study concluded that GCTs are not characterized by
specific chromosomal imbalances.9 Another study an-
alyzed the gene expression profile of a GCT of the
tongue and identified several differentially expressed
genes, including some previously associated with neu-
ral alterations.31
LOH can be assessed by comparing constitutive
normal tissue DNA with tumor tissue DNA using
polymorphic microsatellite markers, and it is re-
garded to be a somatic hallmark of inactivation of a
tumor suppressor gene.24 Deletions in chromosomal
regions of tumor suppressor genes may be involved
in the development of tumors through alterations in
cell cycle control.10-15 In the present study, we found
LOH at 17p13.1 and/or 9p22-p13 chromosomal loci
in 5 of 8 oral GCTs. The alterations at the 17p and 9p
and 17.
owed loss of the long allele compared with DNA of normal
t allele (1) and long allele (2).ple shregions are the most common genetic alterations
and lo
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these regions has been described in other tumor
types, including ameloblastomas, mixed odontogenic
tumors, and oral squamous cell carcinomas.15,17,23
TP53 and P16 are examples of tumor suppressor
genes located on chromosomes 17p and 9p, respec-
tively, close to the markers used in these chromosomal
regions. Recent studies suggest that changes in the
sequences of these loci, specifically LOH in the regions
related to these genes, may modify the reading patterns
of those genes and culminate in haploinsufficiency or
gene silencing.10,32 Alterations in TP53 and P16 genes
can lead to uncontrolled cell cycles and favor tumor
growth.17,23 Alterations in the locus of TP53 may
change the expression of the TP53 gene; nevertheless,
in the present study, the positivity of the p53 protein
was not associated with LOH at 17p13.1 locus. The
literature shows that in normal cells, p53 protein levels
are low due to the activity of E3 ubiquitin ligases, such
as MDM2.33,34 Ubiquitination or phosphorylation of
the MDM2 protein may lead to significant reduction in
p53 degradation and the stabilization of this protein
without DNA alteration.11,35 Furthermore, p53 protein
accumulation can also occur in response to cellular
stresses that may result in the stabilization and accu-
mulation of the protein in the nucleus.36 Finally, it
should be noted that LOH at 17p and 9p markers may
target genes other than TP53 and P16.
As it is not possible to determine the exact develop-
mental stage of each tumor, these genetic alterations
found in the 17p and 9p chromosomal regions may
either represent a driver event related to tumor initia-
tion, or they may represent a consequence of deregu-
lated growth. It is interesting that the presence of the
same alterations in oral leukoplakia seems to be asso-
ciated with a higher risk of malignant transformation.37
We show that similar findings are also observed in
Fig. 3. Example of p53 positive immunostaining not assoc
(original magnification 400) (A), but no LOH for p53 mark
are located at the TP53 gene locus, 17p13.1. Short allele (1)some GCTs, despite its evident benign nature. As wedid not find higher proliferation rates (estimated by
ki-67 positivity) in the samples exhibiting LOH, these
genetic alterations may not be sufficient to cause cell
cycle deregulation in these lesions. These results need
to be further explored in larger cohorts of samples. In
conclusion, our results show evidence of LOH in the
17p and 9p chromosomal regions in oral GCTs. Our
study also demonstrates that these alterations are not
exclusive of potentially malignant or malignant pheno-
type and may be found in benign lesions.
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